Opinion Paper

When to start ART in adults? The results of HPTN 052 move us closer to a test-and-treat policy

Nathan Geffen
Southern African Journal of HIV Medicine | Vol 12, No 3 | a178 | DOI: https://doi.org/10.4102/sajhivmed.v12i3.178 | © 2011 Nathan Geffen | This work is licensed under CC Attribution 4.0
Submitted: 15 December 2011 | Published: 30 September 2011

About the author(s)

Nathan Geffen, Treatment Action Campaign, South Africa


Share this article

Bookmark and Share

Abstract

When is the best time to initiate antiretroviral therapy (ART) in adults? This is a vital question in HIV treatment and prevention services. More specifically, is the 350 cells/µl CD4 count threshold recommended by current World Health Organization (WHO) guidelines sufficient, or should we move to a ‘test-and-treat’ approach in which anyone who tests HIV-positive is offered ART, irrespective of their CD4 count? The recently announced results of the HPTN 052 trial take us closer, but not all the way, to a test-and-treat approach.

Keywords

No related keywords in the metadata.

Metrics

Total abstract views: 1104
Total article views: 2209

 

Crossref Citations

1. Clinical Uncertainties, Health Service Challenges, and Ethical Complexities of HIV “Test-and-Treat”: A Systematic Review
Sonali P. Kulkarni, Kavita R. Shah, Karthik V. Sarma, Anish P. Mahajan
American Journal of Public Health  vol: 103  issue: 6  first page: e14  year: 2013  
doi: 10.2105/AJPH.2013.301273